



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

Note: Bibliography reflects the latest situation

- (15) Correction information:
Corrected version no 1 (W1 B1)
INID code(s) 73
- (51) Int Cl.:
A61K 31/19 ^(1985.01) **A61P 35/00** ^(2000.01)
- (48) Corrigendum issued on:
22.03.2006 Bulletin 2006/12
- (86) International application number:
PCT/EP2002/010419
- (45) Date of publication and mention
of the grant of the patent:
28.12.2005 Bulletin 2005/52
- (87) International publication number:
WO 2003/024442 (27.03.2003 Gazette 2003/13)
- (21) Application number: **02777129.4**
- (22) Date of filing: **17.09.2002**

(54) **Valproic acid for the treatment of breast cancer, colon cancer, head and neck cancer, small cell lung carcinoma and cancer of the blood cells in combination with irradiation**

Valproinsäure zur Behandlung von Brustkrebs, Dickdarmkrebs, Kopf-Hals-Krebs, kleinzelligem Lungenkarzinom und Blutzellenkrebs in Kombination mit Bestrahlung

Acide valproïque pour le traitement des cancers du sein, du colon, de la tête et du cou, du carcinome du poumon à petites cellules et du cancer de cellules sanguines en combinaison avec l'irradiation

- (84) Designated Contracting States:
**AT BE BG CH CY CZ DE DK EE ES FI FR GB GR
IE IT LI LU MC NL PT SE SK TR**
- (30) Priority: **18.09.2001 EP 01121722**
- (43) Date of publication of application:
16.06.2004 Bulletin 2004/25
- (60) Divisional application:
05019659.1 / 1 602 371
05101081.7 / 1 529 527
- (73) Proprietor: **TopoTarget Germany AG**
60596 Frankfurt am Main (DE)
- (72) Inventors:
• **GRONER, Bernd**
60322 Frankfurt am Main (DE)
• **HEINZEL, Thorsten**
60529 Frankfurt am Main (DE)
• **HENTSCH, Bernd**
47239 Duisburg (DE)
• **WELS, Winfried, Stephan**
60599 Frankfurt (DE)
• **HERRLICH, Peter, A.**
76229 Karlsruhe (DE)
- **MINUCCI, Saverio**
Opera (Noverasco), 20090 Milan (IT)
• **PELICCI, Pier, Giuseppe**
I-20090 Opera (IT)
• **GÖTTLICHER, Martin**
76297 Stutensee (DE)
- (74) Representative: **Keller, Günter et al**
Lederer & Keller
Patentanwälte
Prinzregentenstrasse 16
80538 München (DE)
- (56) References cited:
EP-A- 0 360 205 EP-A- 0 412 211
EP-A- 0 632 008 EP-A- 1 170 008
WO-A-01/47533 US-A- 5 672 746
US-A- 5 939 455 US-A- 6 028 102
US-A- 6 110 955 US-B1- 6 207 147
- **AIKEN TC, COLLIN RC: "A possible anti-emetic role for sodium valproate in cytotoxic chemotherapy" BRITISH JOURNAL OF HAEMATOLOGY, vol. 89, no. 4, 4 April 1995 (1995-04-04), pages 903-904, XP008004839**

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- DRIEVER PH, KNÜPFER MM, CINATL J, WOLFF JEA: "Valproic acid for the treatment of pediatric malignant glioma" *KLINISCHE PAEDIATRIE*, vol. 211, July 1999 (1999-07), pages 323-328, XP000997401
- KNÜPFER MM, HERNÁIZ-DRIEVER P, POPPENBORG H, WOLFF JEA, CINATL J: "Valproic Acid Inhibits Proliferation and Changes Expression of CD44 and CD56 of Malignant Glioma Cells in Vitro" *ANTICANCER RESEARCH*, vol. 18, no. 5A, 1998, pages 3585-3589, XP008004824
- YAO C-P, MATHER GG, STEPHENS JR, LEVY RH: "Cytotoxicity Induced by the Combination of Valproic Acid and Tumor Necrosis Factor-alpha" *BIOCHEMICAL PHARMACOLOGY*, vol. 58, 1999, pages 455-459, XP002203825
- VAMECQ J ET AL: "PRELIMINARY STUDIES ABOUT NOVEL STRATEGIES TO REVERSE CHEMORESISTANCE TO ADRIAMYCIN REGARDING GLUTATHIONE METABOLISM, PEROXISOMAL AND EXTRAPEROXISOMAL HYDROPEROXIDE AND VALPROIC ACID METABOLIC PATHWAYS" *BIOLOGY OF THE CELL*, ELSEVIER, PARIS, FR, vol. 77, 1993, pages 17-26, XP008004943 ISSN: 0248-4900
- FISCHKOFF S A ET AL: "INDUCTION OF NEUTROPHILIC DIFFERENTIATION OF HUMAN PROMYELOCYTIC LEUKEMIC CELLS BY BRANCHED-CHAIN CARBOXYLIC ACID ANTICONVULSANT DRUGS" *JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS*, RAVEN PRESS, NEW YORK, NY, US, vol. 3, no. 2, April 1984 (1984-04), pages 132-137, XP000997488 ISSN: 0732-6580
- COURAGE-MAGUIRE C, BACON CL, NAU H, REGAN CM: "Correlation of in vitro anti-proliferative potential with in vivo teratogenicity in a series of valproate analogues" *INT J DEVEL NEUROSCIENCE*, vol. 15, no. 1, 1997, pages 37-43, XP002224044
- NORDENBERG J ET AL: "EFFECTS OF PSYCHOTROPIC DRUGS ON CELL PROLIFERATION AND DIFFERENTIATION" *BIOCHEMICAL PHARMACOLOGY*, PERGAMON, OXFORD, GB, vol. 58, no. 8, 15 October 1999 (1999-10-15), pages 1229-1236, XP001027786 ISSN: 0006-2952
- CINATL J JR, CINATL J, SCHOLZ M, HERNÁIZ-DRIEVER P, HENRICH D, KABICKOVA H, VOGEL J-U, DOERR HW, KORNUBER B: "Antitumor activity of sodium valproate in cultures of human neuroblastoma cells" *ANTI-CANCER DRUGS*, vol. 7, no. 7, July 1996 (1996-07), pages 766-773, XP008004842
- CINATL J ET AL: "SODIUM VALPROATE INHIBITS IN VIVO GROWTH OF HUMAN NEUROBLASTOMA CELLS" *ANTI-CANCER DRUGS*, OXFORD, GB, vol. 8, no. 10, November 1997 (1997-11), pages 958-963, XP000997406 ISSN: 0959-4973
- TITTLE T V ET AL: "EFFECT OF ANTIEPILEPTIC DRUGS ON GROWTH OF MURINE LYMPHOID TUMOR CELLS IN SINGLE-CELL CULTURE" *EPILEPSIA*, RAVEN PRESS LTD., NEW YORK, US, vol. 33, no. 4, July 1992 (1992-07), pages 729-735, XP000997403 ISSN: 0013-9580
- DATABASE MEDLINE [Online] November 1978 (1978-11) MORI H ET AL: "[Effect of alpha-mercaptopropionylglycine (alpha-MPG) and sodium dipropylacetate (DPA) on antibody formation (IV). Tumor immunity (author's transl)]" Database accession no. NLM374206 XP002166105 & NIPPON YAKURIGAKU ZASSHI. *JAPANESE JOURNAL OF PHARMACOLOGY*. JAPAN NOV 1978, vol. 74, no. 8, November 1978 (1978-11), pages 907-923, ISSN: 0015-5691
- LETIZIA C ET AL: "REDUCTION OF AN ACTH SECRETING ADENOMA IN A PATIENT WITH NELSON'S SYNDROME CHRONICALLY TREATED WITH SODIUM VALPROATE" *EUROPEAN JOURNAL OF INTERNAL MEDICINE*, ELSEVIER, AMSTERDAM,, NL, vol. 5, no. 4, October 1994 (1994-10), pages 325-328, XP000997468 ISSN: 0953-6205
- GROSSMAN SA, HOCHBERG F, FISHER J, CHEN TL, KIM L, GREGORY R, GROCHOW LB, PIANTADOSI S: "Increased 9-aminocamptothecin dose requirements in patients on anticonvulsants" *CANCER CHEMOTHER. PHARMACOL.*, vol. 42, 1998, pages 118-126, XP002202988
- STÄNDER M, DICHGANS J, WELLER M: "Anticonvulsant drugs fail to modulate chemotherapy-induced cytotoxicity and growth inhibition of human malignant glioma cells" *JOURNAL OF NEURO-ONCOLOGY*, vol. 37, no. 3, May 1998 (1998-05), pages 191-198, XP008004836
- TITTLE TV, SCHAUMANN BA, RAINEY JE, TAYLOR K: "Segregation of the Growth Slowing Effects of Valproic Acid from Phenytoin and Carbamazepine on Lymphoid Tumor Cells" *LIFE SCIENCES*, vol. 50, no. 14, 1992, pages PL79-PL83, XP008005297
- LAMPEN A ET AL: "NEW MOLECULAR BIOASSAYS FOR THE ESTIMATION OF THE TERATOGENIC POTENCY OF VALPROIC ACID DERIVATIVES IN VITRO: ACTIVATION OF THE PEROXISOMAL PROLIFERATOR-ACTIVATED RECEPTOR (PPARDELTA)" *TOXICOLOGY AND APPLIED PHARMACOLOGY*, ACADEMIC PRESS, SAN DIEGO, CA,, US, vol. 160, no. 3, 1 November 1999 (1999-11-01), pages 238-249, XP000987176 cited in the application
- VAMECQ J ET AL: "PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPARS) AND THEIR IMPLICATIONS IN DISEASES" *CURRENT OPINION IN ENDOCRINOLOGY AND DIABETES*, PHILADELPHIA, PA, US, vol. 7, no. 1, 2000, pages 8-18, XP000909179 ISSN: 1068-3097

- VAMECQ J ET AL: "Medical significance of peroxisome proliferator-activated receptors" LANCET, vol. 354, no. 9173, 10 July 1999 (1999-07-10), pages 141-148, XP004266618 ISSN: 0140-6736
- RAYNER A A ET AL: "LYMPHOKINE-ACTIVATED KILLER (LAK) CELLS ANALYSIS OF FACTORS RELEVANT TO THE IMMUNOTHERAPY OF HUMAN CANCER" CANCER, AMERICAN CANCER SOCIETY, PHILADELPHIA, PA, US, vol. 55, no. 3, 15 March 1985 (1985-03-15), pages 1327-1333, XP000108155 ISSN: 0008-543X

Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

专利名称(译)	丙戊酸用于治疗乳腺癌，结肠癌，头颈癌，小细胞肺癌和血细胞癌与放射治疗相结合		
公开(公告)号	EP1427403B8	公开(公告)日	2006-03-22
申请号	EP2002777129	申请日	2002-09-17
[标]申请(专利权)人(译)	G2M癌症DRUSG		
申请(专利权)人(译)	G2M抗癌药物AG		
当前申请(专利权)人(译)	TOPOTARGET德国AG		
[标]发明人	GRONER BERND HEINZEL THORSTEN HENTSCH BERND WELS WINFRIED STEPHAN HERRLICH PETER A MINUCCI SAVERIO PELICCI PIER GIUSEPPE GOTTLICHER MARTIN		
发明人	GRONER, BERND HEINZEL, THORSTEN HENTSCH, BERND WELS, WINFRIED, STEPHAN HERRLICH, PETER, A. MINUCCI, SAVERIO PELICCI, PIER, GIUSEPPE GÖTTLICHER, MARTIN		
IPC分类号	A61K31/19 A61P35/00 G01N33/50 A61K31/20 A61K31/203 A61K31/28 A61K31/59 A61K31/593 A61K39/00 A61K39/395 A61K45/00 A61K45/06 A61P43/00 G01N33/15 G01N33/53 G01N33/566 G01N33/574		
CPC分类号	A61K45/06 A61K31/19 A61K31/20 A61K31/28 A61K31/59		
代理机构(译)	KELLER , GUNTER		
优先权	2001121722 2001-09-18 EP		
其他公开文献	EP1427403B1 EP1427403A2		
外部链接	Espacenet		

摘要(译)

本发明涉及药物丙戊酸及其衍生物作为具有组蛋白脱乙酰基酶的酶的抑制剂用于人癌症的敏化治疗的用途，其与已建立的治疗原理相结合。本发明还涉及这些化合物用于治疗肿瘤转移和微小残留疾病的用途。本发明的另一方面是鉴定可用于组合癌症治疗的物质的方法和鉴定肿瘤的诊断方法，包括体外测试肿瘤是否对VPA或其衍生物的组合和已建立的肿瘤的治疗有反应的步骤。本发明包括制备用于治疗人类癌症的临床使用的物质。

